YmAbs Therapeutics (YMAB)
(Real Time Quote from BATS)
$6.62 USD
+0.29 (4.58%)
Updated Jan 15, 2025 09:58 AM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
YMAB 6.62 +0.29(4.58%)
Will YMAB be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for YMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for YMAB
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?
YMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates
Other News for YMAB
Cautious Outlook on Y-Mabs Therapeutics Amid Restructuring and Growth Uncertainty
Y-mAbs Therapeutics Updates on Business and Clinical Trials
Y-mAbs Therapeutics guides FY2024 revenue below estimates
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA